nivolumab,etigilimab
mereo biopharmaceuticalceutical,bms,marker therapeutics
['vance', 'solid tumor', 'nivolumab', 'biomarker', 'etigilimab', 'able,(-kable),(-eable)', 'nivo', 'marker ', 'imab ', 'mereo ']
we are excited to share biomarker analysis of etigilimab + nivolumab in select recurrent advanced/metastatic solid tumors at the upcoming #esmo2022. the poster will be available to view from 9am central european time, sat 10 sept. 
Mereo is a clinical-stage company focused on developing therapies in oncology & #orphandrugs / #rarediseasetherapies for #rarediseases